Fed Regist. 2012 Jul 6;77(130):39924-7.
The Food and Drug Administration (FDA) is issuing a final rule to require the filing of a premarket approval application (PMA) or a notice of completion of a product development protocol (PDP) for the cardiovascular permanent pacemaker electrode. The Agency has summarized its findings regarding the degree of risk of illness or injury designed to be eliminated or reduced by requiring the device to meet the statute's approval requirements and the benefits to the public from the use of the device. This action implements certain statutory requirements.
美国食品药品监督管理局(FDA)正在发布一项最终规则,要求提交心血管永久性起搏器电极的上市前批准申请(PMA)或产品开发协议完成通知(PDP)。该机构总结了其关于通过要求该设备符合法规的批准要求而旨在消除或降低的疾病或伤害风险程度的调查结果,以及使用该设备给公众带来的益处。此行动实施了某些法定要求。